Loading
Total declarations
Company
▲ Purchases (1 ops.)
▼ Sales (0 ops.)
Latest filing published 10 Feb 2023 for Processa Pharmaceuticals, Inc., €7,466. Read the official filing
Filing timeline
BuySaleRobert Michael Floyd
Insider track record
Disclosed buys
1
Disclosed sells
0
T+90 hit rate
100%
T+90 mean return
+15.7%
Across 1 buy signal with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Robert Michael Floyd: trading record in brief
Robert Michael Floyd (chief executive) discloses dealings in Processa Pharmaceuticals, Inc. to SEC (Form 4). Between 22 June 2021 and 9 February 2023, the trades on record add up to 6 filings.
No open-market sale appears; the market trades are 1 purchase worth €12k. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. The rest of the record consists of 1 share grant and 2 option exercises.
The latest filing, published on 10 February 2023, reports a share grant of €7,466 in Processa Pharmaceuticals, Inc. The most recent open-market purchase was published on 22 June 2021, 1,944 days ago. The median gap between a trade and its publication by SEC (Form 4) is 4 days. For comparison, the SEC allows two business days to file a Form 4. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Companies and markets linked to Robert Michael Floyd
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations6 total
10,000 shares@ US$0.8024.1% of flowCommon StockSEC:0001567619-23-002404:0
12,500 sharesCommon StockSEC:0001567619-22-018383:0
7,000 shares0Common StockSEC:0001567619-22-016598:0
7,000 shares0Common StockSEC:0001567619-22-007993:0
12,500 sharesCommon StockSEC:0001567619-21-018171:0
2,000 shares@ US$7.029261.2% of flowCommon StockSEC:0001567619-21-012496:0
Canonical exit: 20 Sept 2021 (T+90)
6 of 6 declarations
